Reports
As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.
Global Gemcitabine HCL Market: By Type: Branded, Generic: By Application: Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small-Cell Lung Carcinoma (NSCLC), Others; By End Use; Regional Analysis; Historical Market and Forecast (2016-2026); Market Dynamics; Competitive Landscape; Industry Events and Developments
Global Gemcitabine HCL Market Outlook
The global gemcitabine HCL market is projected to grow at a CAGR of 6.5% during the forecast period of 2021-2026. With the rise in demand for chemotherapy to treat various kinds of cancer, including breast cancer, ovarian cancer, and non-small cell lung cancer, the gemcitabine HCL market is witnessing a significant growth.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Properties and Applications
Gemcitabine HCL can be used alone or with a combination of other drugs to treat cancers like breast cancer, non-small cell lung cancer, ovarian cancer, and pancreatic cancer.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The global gemcitabine HCL market can be segmented based on types, applications, end-uses, and regions.
Based on its types, the industry can be categorised as branded and generic.
Based on its application, the gemcitabine HCL market can be segmented into:
- Pancreatic Cancer
- Breast Cancer
- Ovarian Cancer
- Non-Small-Cell Lung Carcinoma (NSCLC)
- Others
Based on its end-uses, the industry can be segmented as hospitals and cancer centres, among others.
The EMR report looks into the regional gemcitabine HCL markets like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Analysis
This increase in the number of cancer cases, along with the rising geriatric population and the associated risk factors, is driving the industry for gemcitabine HCL. Further, with the rise in the number of governmental and healthcare patient support organisations and agencies, which are spreading awareness regarding cancer, the industry is expected to receive a further boost. Technical advancements in the production of generic drugs have led to an increase in the demand for gemcitabine HCl, which is expected to propel the global gemcitabine HCl market over the forecast period.
Competitive Landscape
The report presents a detailed analysis of the following key players in the global gemcitabine HCL market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- Eli Lilly and Company (NYSE: LLY)
- Teva Pharmaceutical Industries Ltd.
- Accord Healthcare Ltd.
- Pfizer, Inc.
- Mylan N.V.
- Sun Pharmaceutical Industries Ltd.
- Fresenius Kabi AG
- Dr. Reddy’s Laboratories Ltd.
- Others
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2020 |
| Historical Period | 2016-2020 |
| Forecast Period | 2021-2026 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Type, Application, End Use, Region |
| Breakup by Type | Branded, Generic |
| Breakup by Application | Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small-Cell Lung Carcinoma (NSCLC), Others |
| Breakup by End Use | Hospitals, Cancer Centres, Others |
| Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Market Dynamics | SWOT, Porter's Five Forces, EMR’s Key Indicators for Price and Demand |
| Price Analysis | Historical and Forecast Price Trends- Regional |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | Eli Lilly and Company (NYSE: LLY), Teva Pharmaceutical Industries Ltd. (TLV: TEVA), Accord Healthcare Ltd., Pfizer, Inc. (NYSE: PFE), Mylan N.V. (NASDAQ: MYL), Sun Pharmaceutical Industries Ltd. (NSE: SUNPHARMA), Fresenius Kabi AG, Dr. Reddy’s Laboratories Ltd. (NSE: DRREDDY), Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
Key Questions Answered in the Market Report
- How has the global gemcitabine HCL market performed in the previous years (2016-2020)?
- What is the forecast assessment of the gemcitabine HCL market for 2021-2026?
- What are the major drivers for the historical (2016-2020) and forecast (2021-2026) periods?
- What are the major constraints for the historical (2016-2020) and forecast (2021-2026) periods?
- Who are the key manufacturers of gemcitabine HCL in the global market?
- What are the price trends of gemcitabine HCL in the market globally?
- What are the import and export trends in the global gemcitabine HCL market?
- Who are the top importers and exporters of gemcitabine HCL in the industry globally?
- What is the degree of competition in the global gemcitabine HCL market?
- What are the major events and developments taking place within the industry globally?
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
1.1 Objectives of the Study
1.1.1 Research Objective
1.1.2 Key Findings of the Report
2 Research Methodology
2.1 Data Extraction
2.2 Data Corroboration
2.3 Market Structure
2.4 Assumptions
2.5 Market Models
3 Introduction
3.1 Market Outlook
3.2 Key Industry Trends
3.3 Market Scope and Segmentation
3.4 Additional Insights
4 Executive Summary
4.1 Key Market Developments
4.2 Market Analysis
4.3 Key Players
4.4 Cost Structure
4.5 Market Revenue and Growth
5 Market Dynamics
5.1 Market Driver Analysis
5.2 Market Restraint Analysis
5.3 Industry Challenges
5.4 Industry Opportunities
6 Global Gemcitabine HCL Market Analysis
6.1 Global Gemcitabine HCL Historical Market (2016-2020) & Forecast (2021-2026)
6.2 Global Gemcitabine HCL Market Breakup by Type
6.2.1 Branded
6.2.2 Generic
6.3 Global Gemcitabine HCL Market Breakup by Type: Historical Market (2016-2020) & Forecast (2021-2026)
6.3.1 Branded
6.3.2 Generic
6.4 Global Gemcitabine HCL Market Breakup by Application
6.4.1 Pancreatic Cancer
6.4.2 Breast Cancer
6.4.3 Ovarian Cancer
6.4.4 Non-Small-Cell Lung Carcinoma (NSCLC)
6.4.5 Others
6.5 Global Gemcitabine HCL Market Breakup by Application: Historical Market (2016-2020) & Forecast (2021-2026)
6.5.1 Pancreatic Cancer
6.5.2 Breast Cancer
6.5.3 Ovarian Cancer
6.5.4 Non-Small-Cell Lung Carcinoma (NSCLC)
6.5.5 Others
6.6 Global Gemcitabine HCL Market Breakup by End Use
6.6.1 Hospitals
6.6.2 Cancer Centres
6.6.3 Others
6.7 Global Gemcitabine HCL Market Breakup by End Use: Historical Market (2016-2020) & Forecast (2021-2026)
6.7.1 Hospitals
6.7.2 Cancer Centres
6.7.3 Others
6.8 Global Gemcitabine HCL Market Breakup by Region
6.8.1 North America
6.8.1.1 United States of America
6.8.1.2 Canada
6.8.2 Europe
6.8.2.1 Germany
6.8.2.2 United Kingdom
6.8.2.3 France
6.8.2.4 Italy
6.8.2.5 Others
6.8.3 Asia Pacific
6.8.3.1 China
6.8.3.2 Japan
6.8.3.3 India
6.8.3.4 ASEAN
6.8.3.5 Others
6.8.4 Latin America
6.8.4.1 Brazil
6.8.4.2 Argentina
6.8.4.3 Mexico
6.8.4.4 Others
6.8.5 Middle East & Africa
6.8.5.1 Saudi Arabia
6.8.5.2 United Arab Emirates
6.8.5.3 Nigeria
6.8.5.4 South Africa
6.8.5.5 Others
6.9 Global Gemcitabine HCL Market Breakup by Region: Historical Market (2016-2020) & Forecast (2021-2026)
6.9.1 North America
6.9.1.1 United States of America
6.9.1.2 Canada
6.9.2 Europe
6.9.2.1 Germany
6.9.2.2 United Kingdom
6.9.2.3 France
6.9.2.4 Italy
6.9.2.5 Others
6.9.3 Asia Pacific
6.9.3.1 China
6.9.3.2 Japan
6.9.3.3 India
6.9.3.4 ASEAN
6.9.3.5 Others
6.9.4 Latin America
6.9.4.1 Brazil
6.9.4.2 Argentina
6.9.4.3 Mexico
6.9.4.4 Others
6.9.5 Middle East & Africa
6.9.5.1 Saudi Arabia
6.9.5.2 United Arab Emirates
6.9.5.3 Nigeria
6.9.5.4 South Africa
6.9.5.5 Others
7 SWOT Analysis
7.1 Overview
7.2 Strengths
7.3 Weaknesses
7.4 Opportunities
7.5 Threats
8 Porter’s Five Forces Analysis
8.1 Overview
8.2 Buyer’s Power
8.3 Supplier’s Power
8.4 New Entrants
8.5 Degree of Rivalry
8.6 Substitutes
9 Regional Price Analysis
9.1 North America Historical Price Trends (2016-2020) & Forecast (2021-2026)
9.2 Europe Historical Price Trends (2016-2020) & Forecast (2021-2026)
9.3 Asia Pacific Historical Price Trends (2016-2020) & Forecast (2021-2026)
9.4 Latin America Historical Price Trends (2016-2020) & Forecast (2021-2026)
9.5 Middle East & Africa Historical Price Trends (2016-2020) & Forecast (2021-2026)
10 Competitive Landscape & Supplier Analysis
10.1 Eli Lilly and Company (NYSE: LLY)
10.1.1 Company Overview
10.1.2 Financial Analysis
10.2 Teva Pharmaceutical Industries Ltd. (TLV: TEVA)
10.2.1 Company Overview
10.2.2 Financial Analysis
10.3 Accord Healthcare Ltd.
10.3.1 Company Overview
10.3.2 Financial Analysis
10.4 Pfizer, Inc. (NYSE: PFE)
10.4.1 Company Overview
10.4.2 Financial Analysis
10.5 Mylan N.V. (NASDAQ: MYL)
10.5.1 Company Overview
10.5.2 Financial Analysis
10.6 Sun Pharmaceutical Industries Ltd. (NSE: SUNPHARMA)
10.6.1 Company Overview
10.6.2 Financial Analysis
10.7 Fresenius Kabi AG
10.7.1 Company Overview
10.7.2 Financial Analysis
10.8 Dr. Reddy’s Laboratories Ltd. (NSE: DRREDDY)
10.8.1 Company Overview
10.8.2 Financial Analysis
10.9 Others
11 Industry Events and Developments
Additional Customisations Available:
1 Manufacturing Process
1.1 Detailed Process Flow
1.2 Operations Involved
1.3 Mass Balance
2 Cost Analysis
2.1 Land, Location and Site Development
2.2 Construction
2.3 Plant Machinery
2.4 Cost of Raw Material
2.5 Packaging
2.6 Transportation
2.7 Utilities
2.8 Manpower
2.9 Other Capital Investment
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2699-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateFive User License
$3699-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4699-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?RIGHT PEOPLE
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
RIGHT METHODOLOGY
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
RIGHT PRICE
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
RIGHT SUPPORT
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
The global telmisartan market attained a value of about USD 3,574 million in 2020, driven by the rising cases of hypertension and cardiovascular diseases. Aided by the robustly growing pharmaceutical ...
The global doxorubicin market attained a value of about USD 1,075.90 million in 2020, driven by the rising cases of cancer worldwide. Aided by government investments in the pharmaceutical sector, the ...
The global radiopharmaceuticals market attained a value of about USD 4.3 billion, driven by rising applications in diagnostic and therapeutic segment. Aided by constant research and development and ri...
The global anticoagulants market is driven by the rising prevalence of various cardiovascular diseases. Aided by the growing adoption of safer and more efficient anticoagulants, the market is expected...
The global acne medication market attained a value of nearly USD 8.9 billion in 2020, driven by the rising prevalence of acne disorders and the growing advancements in developing acne treatment soluti...
NEWSLETTER